All In Biotech

Drug Trial Radar · NCT05513001

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous Urticaria Patients Who Completed the Preceding Remibrutinib Phase 3 Studies

Last checked: Nov 19, 2026Latest source record: Mar 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 696 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

696

Actual

Start

Dec 9, 2022

Primary completion

Aug 26, 2024

Study completion Aug 2, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Aug 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the treatment phase of remibrutinib preceding Phase 3 core studies. This study will also fulfill the Novartis commitment to provide post-trial access to participants who have completed the preceding Phase 3 studies, where applicable.

Conditions

  • Chronic Spontaneous Urticaria

Interventions

  • LOU064 (blinded)Drug

    LOU064 (blinded) active treatment

  • PlaceboDrug

    Placebo

  • LOU064 (open label)Drug

    LOU064 (open-label) active treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first composite event (i.e., relapse (UAS7≥16)Time frame: 24 weeks

Locations

208 sites in 30 countries. Site status is shown where the registry gives one.

  • Allervie Clinical Research

    Birmingham, Alabama

  • Cahaba Derm and skin hlth ctr 27

    Birmingham, Alabama

  • Research Solutions of Arizona

    Litchfield Park, Arizona

  • Acuro Research Inc

    Little Rock, Arkansas

  • Arkansas Research Trials

    North Little Rock, Arkansas

  • Kern Research

    Bakersfield, California

  • Antelope Valley Clinical Trials

    Lancaster, California

  • Allergy and Asthma Consultants

    Redwood City, California

  • Asthma and Allergy Associates P C

    Colorado Springs, Colorado

  • Colorado Allergy and Asthma Ctr PC

    Denver, Colorado

  • UCONN Health Dermatology

    Farmington, Connecticut

  • Florida Ctr Allergy Asthma Research

    Aventura, Florida

  • Finlay Medical Research

    Greenacres City, Florida

  • Miami Dade Medical Research

    Miami, Florida

  • Sarasota Clinical Research

    Sarasota, Florida

  • Allergy and Asthma Diagnostic Treatment Center

    Tallahassee, Florida

  • Aeroallergy Research Laboratories

    Savannah, Georgia

  • Treasure Valley Medical Research

    Boise, Idaho

  • Endeavor Health

    Glenview, Illinois

  • Asthma and Allergy Center of Chicago S C

    River Forest, Illinois

  • Deaconess Clin Allerg Res Inst

    Evansville, Indiana

  • The Indiana Clinical Trials Center

    Plainfield, Indiana

  • Allergy and Asthma Specialist P S C

    Owensboro, Kentucky

  • John Hopkins University

    Baltimore, Maryland

  • Institute for Asthma and Allergy PC

    Chevy Chase, Maryland

  • The Clinical Research Center

    St Louis, Missouri

  • Somnos Clinical Research

    Lincoln, Nebraska

  • Allergy Asthma Assoc Monmouth

    Little Silver, New Jersey

  • Oakview Dermatology

    Athens, Ohio

  • CR Services Acquisition US

    Columbus, Ohio

  • Optimed Research LLC

    Columbus, Ohio

  • Toledo Institute of Clinical Research

    Toledo, Ohio

  • Allergy Asthma and Clinical Research

    Oklahoma City, Oklahoma

  • Vital Prospects Clinical Research Institute

    Tulsa, Oklahoma

  • Allergy and Clinical Immunology Associates

    Pittsburgh, Pennsylvania

  • National Allergy and Asthma Research LLS

    North Charleston, South Carolina

  • Orion Clinical Research

    Austin, Texas

  • Western Sky Medical Research

    El Paso, Texas

  • RFSA Dermatology

    San Antonio, Texas

  • Allergy Associates of Utah

    Sandy City, Utah

Showing 40 of 208 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.